Over the past 7 days, the market is flat, but is up 21% over the past year, with earnings expected to grow 15% annually. In this environment, identifying high-growth technology stocks that match these optimistic projections can be critical for investors looking to capitalize on future opportunities.

The 10 fastest growing technology companies in the USA

Click here to see the full list of 250 stocks from our high-growth US tech and AI stocks screener.

We examine a selection of our screener results.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mirum Pharmaceuticals, Inc., a $2.11 billion biopharmaceutical company, is focused on developing and commercializing novel therapies for debilitating rare and orphan diseases.

Operations: Mirum Pharmaceuticals, Inc. generates its revenue primarily from the pharmaceutical segment, which recorded revenue of $264.38 million. The company focuses on the development and commercialization of therapies for rare and orphan diseases.

Mirum Pharmaceuticals reported significant revenue growth, increasing 107.7% to $77.88 million in the second quarter of 2024 compared to the same period last year. Despite a net loss of $24.64 million, this is an improvement from the prior year loss of $74.04 million, driven by strategic R&D investments totaling $25 million aimed at expanding the product line and improving treatment efficacy in rare liver diseases such as PFIC and CTX. The recent FDA approval of the product approval extension for LIVMARLI further positions Mirum as a key player in addressing unmet medical needs in pediatric hepatology and could drive future revenue growth and market penetration.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and rare lung diseases and has a market capitalization of approximately $1.48 billion.

Operations: MannKind Corporation’s revenues are primarily from the sale of pharmaceuticals and amount to $248.37 million. The company focuses on inhaled therapeutic products for the treatment of endocrine and rare lung diseases in the United States.

MannKind’s revenue increased significantly to $72.39 million in the second quarter of 2024, up from $48.61 million a year earlier, driven by advances in inhaled insulin products such as Afrezza. The company’s earnings are expected to grow an impressive 38.4% annually over the next three years, outpacing the U.S. market average growth of 15.2%. With research and development spending playing a critical role, MannKind has invested significantly in innovative treatments and strategic partnerships, such as its recent collaboration with Pulmatrix to treat neurological conditions with the Cricket inhaler.

Simply Wall St Growth Rating: ★★★★☆☆

Overview: BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small molecule and protein therapeutics to treat rare diseases and has a market capitalization of $1.70 billion.

Operations: BioCryst Pharmaceuticals focuses on developing oral small molecule and protein therapeutics for rare diseases and generates revenue of $382.24 million from its Biotechnology segment. The company has a market capitalization of approximately $1.70 billion.

BioCryst Pharmaceuticals reported revenues in the second quarter of 2024 increased to $109.33 million from $82.49 million a year ago, while net loss narrowed significantly to $12.67 million from $75.33 million. The company’s R&D spending is notable and reflects a strategic focus on innovation and development, with significant investments driving future growth prospects. Although BioCryst was recently removed from several indices, the company has revised its 2024 revenue forecast for ORLADEYO upward to $420 million to $435 million, demonstrating confidence in its product pipeline and market potential.

Summarize everything

• Click here to access our full index of 250 high-growth US technology and AI stocks.
• Are you a shareholder in one or more of these companies? Make sure you’re never caught off guard by adding your portfolio to Simply Wall St and receive timely alerts about important stock developments.
• Simply Wall St is your key to unlocking global market trends, a free, easy-to-use app for forward-thinking investors.

Would you like to explore some alternatives?

This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.

Do you have feedback on this article? Are you interested in the content? Contact us directly. Alternatively, send an email to [email protected]